Key Highlights

  • Third-quarter Revenue rose 6.3% to USD 7.6 million.
  • Nine-month revenue increased 13.7% to USD 23.1 million.
  • Gamma Knife procedures increased approximately 11% in the quarter and nine months.
  • Cash, cash equivalents and restricted cash were approximately USD 9.5 million.

American Shared Hospital Services (NYSE American:AMS) reported third-quarter 2026 total revenue of USD 7.6 million, up 6.3% from USD 7.2 million in the third quarter of 2025. The Earnings table shows an estimate of USD 8.53 million. Loss per share was USD 0.09, against an estimate of earnings of USD 0.01.

Management said its broader priority remains disciplined management of its assets, strengthening its financial foundation and pursuing strategic opportunities that can contribute to sustainable Long-term Growth and Shareholder value.

Revenue, Costs and Nine-Month Results

Revenue from the company's three Rhode Island radiation therapy facilities and its Puebla, Mexico Facility increased 13.5% to USD 3.3 million, compared with USD 2.9 million in the third quarter of 2025. Total costs of revenue increased to USD 6.1 million from USD 5.6 million.

For the first nine months of 2026, total revenue increased 13.7% to USD 23.1 million, against USD 20.4 million in the first nine months of 2025. The company reported a net loss attributable to American Shared Hospital Services of USD 1.7 million, or USD 0.26 per diluted share. That compares with a net loss of USD 922,000, or USD 0.14 per diluted share, in the first nine months of 2025.

Gamma Knife and Radiation Therapy Operations

Management said its international Gamma Knife operations continue to perform well. Total Gamma Knife procedures increased approximately 11% in both the third quarter and the first nine months compared with the prior-year periods. Its Gamma Knife facilities in Peru and Ecuador contributed to growth in patient procedures.

In Peru, the upgrade to the Elekta Leksell Gamma Knife Esprit system has supported improved treatment efficiency, resulting in shorter treatment times, according to management. In Rhode Island, radiation therapy operations remain an important component of the direct patient services business.

Management said the company's operations include radiation therapy facilities in Rhode Island and Puebla, Mexico, as well as Gamma Knife facilities in Peru and Ecuador.

Balance Sheet, Development Projects and Financing Discussions

At September 30, 2026, the company had cash, cash equivalents and restricted cash of approximately USD 9.5 million, compared with USD 3.7 million at December 31, 2025. The current portion of long-term debt, net, was USD 15.7 million, a decrease from USD 17.3 million at December 31, 2025.

Management described a joint venture with Hospital San Javier in Guadalajara, Mexico, as an important international development initiative. It said it currently projects the facility to begin treating patients in mid-2027, and described the project as an opportunity to expand its presence in an important market.

Management also said it continues to focus on its Capital Structure and evaluate alternatives, and that it has been working with its lenders and other Stakeholders on these matters.

The reported items are third-quarter revenue of USD 7.6 million, nine-month revenue of USD 23.1 million, a nine-month net loss of USD 1.7 million, cash of USD 9.5 million and the current portion of long-term Debt of USD 15.7 million. The company announced a call and webcast to discuss the results, with a replay available through November 19, 2026. The company's shares are listed on the NYSE American.